Embed Size (px)
Citation preview
2
3
1 Company Overview
2 Hanmi R&D
3 Beijing Hanmi
4 Financial Results
5 Appendix
4
(Automated Drug Packaging System Company)
805.0
187.1 162.6 170.7
192.9 209.8
0
200
400
600
0
500
1,000
1,500
2015 2016 2017 2018 2019
Sales R&D
1,317.5(Incl. Upfront/Milestones)Sales
(bn KRW)R&D
(bn KRW)
14.2%18.4% 18.6%
19.0%18.8%
5
916.6882.7
1,016.0
1,113.6
Upfront/Milestones
6
7
8
AG
LYCO
SYLATED
FC
AG
LYCO
SYLATED
FC
AG
LYCO
SYLATED
FC
AG
LYCO
SYLATED
FC
Longer Duration
Efficacy & Safety ↑
9
Key Features
Seeking collaboration opportunities
Pre-clinical Phase 1 Phase 2 Phase 3 Registration
Obesity/NASH/Diabetes
LAPSGlucagon ComboHM14320Obesity/Diabetes/NASH
LAPSTriple AgonistHM15211NASH
LAPSGLP/GCGHM12525AObesity
LAPSExd4 AnalogEfpeglenatideDiabetes
LAPSInsulin ComboHM14220Diabetes
LAPSGlucagon AnalogHM15136Obesity
LAPInsulin148HM12480Diabetes
LAPSInsulinHM12460A/HM12470Diabetes
Oncology
EZH1/2 Inhibitor
Solid tumor
Pan-RAF InhibitorBelvarafenibSolid tumor
Pan-HER InhibitorPoziotinibSolid tumor
Oraxol™Paclitaxel+encequidarBreast cancer, solid tumor
LAPSGCSF AnalogEflapegrastimNeutropenia
LSD1 Inhibitor
SCLC, AML
FLT3 InhibitorHM43239AML
Oratecan™Irinotecan+encequidarSolid tumor
ADOR Antagonist
Solid tumor
PD-1/HER2 BsAbBH2950Solid tumor
Oradoxel™Docetaxel+encequidarSolid tumor
GBM Stem Cell TherapyHM21001Glioblastoma
FLX475 (CCR4 Inhibitor)
Solid tumor
Immuno-oncology BsAb
Solid tumor
PD-L1/CD47 BsAb
Solid tumor, Hematologic cancers
Rare Diseases/Other
LAPSASBHM15450Mucopolysaccharidosis
LAPSGlucagon AnalogHM15136Congenital Hyperinsulinism
LAPShGHEfpegsomatropinGH deficiency
LAPSGLP-2 AnalogHM15912Short Bowel Syndrome
Luminate®
Integrin inhibitorDME
Luminate®
Integrin inhibitorRetinitis Pigmentosa
BTK InhibitorHM71224Autoimmune disease 10
B
B
B
B Beijing Hanmi
11
Delivering double-digit growth in domestic market with core
value-added products
Launching 2~3 value-added products annually
Seeking partners for emerging markets
Domestic business growth
2019
Hanmi
597.6
551.8
2018
578.7
2017
526.8
2016
805.0882.7
916.6
1,016.0
675.4
1,113.6
2015
13.0%Korea
Total
Top value-added products
*IMD (Incrementally Modified Drug); **FDC (Fixed Dose Combination)
12
Sales force 1,000+
About 70% : Doctors and Pharmacists
Directly covering 9,000 hospitals and over
150,000 doctors, keeping the No.1
position in pediatric drug market.
Sales & MarketingManufacturingBeijing R&D center
New Biologics BIO ProductionNCE
- Auto-immune
- Oncology
- Diabetes
- Obesity
- Oncology
- PENTAMBODY
PhD. 5, MS. 74
Est. Oct 2008
Animal facility for rodents, beagles,
and primates
High-tech enterprise certification
Focus areas
R&D staffs 150+ GMP sites
To provide FPP to
Chinese market
13
14
15
DEC
16
17
18
19
164.839.90.012.2
20
21
22
24.2% 13.0%
39.7% 11.7%
16.4% -7.5%
12.1% -4.5%
21.0% 15.1%
35.1% 13.8%
12.9% -5.4%
8.8% -2.3%
23
22.2%
59.8%
70.9%
-15.3%
24
15.1% 10.5%
8.8% 5.8%
17.3% 13.9%
11.4% 7.6%
15.6% 8.1%
-7.9% -11.3%
7.2% -15.1%
13.4% 24.5%
25
26
27
28
